PL3883936T3 - Nowe związki heterocykliczne - Google Patents
Nowe związki heterocykliczneInfo
- Publication number
- PL3883936T3 PL3883936T3 PL19809026.8T PL19809026T PL3883936T3 PL 3883936 T3 PL3883936 T3 PL 3883936T3 PL 19809026 T PL19809026 T PL 19809026T PL 3883936 T3 PL3883936 T3 PL 3883936T3
- Authority
- PL
- Poland
- Prior art keywords
- heterocyclic compounds
- new heterocyclic
- new
- compounds
- heterocyclic
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18207725 | 2018-11-22 | ||
PCT/EP2019/081870 WO2020104494A1 (en) | 2018-11-22 | 2019-11-20 | New heterocyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3883936T3 true PL3883936T3 (pl) | 2023-11-20 |
Family
ID=64453331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL19809026.8T PL3883936T3 (pl) | 2018-11-22 | 2019-11-20 | Nowe związki heterocykliczne |
Country Status (31)
Country | Link |
---|---|
US (1) | US20210387999A1 (pl) |
EP (1) | EP3883936B1 (pl) |
JP (1) | JP7444882B2 (pl) |
KR (1) | KR20210094540A (pl) |
CN (1) | CN113166170A (pl) |
AR (1) | AR117139A1 (pl) |
AU (1) | AU2019383500A1 (pl) |
BR (1) | BR112021009348A2 (pl) |
CA (1) | CA3119506A1 (pl) |
CL (1) | CL2021001330A1 (pl) |
CO (1) | CO2021007056A2 (pl) |
CR (1) | CR20210247A (pl) |
DK (1) | DK3883936T3 (pl) |
ES (1) | ES2955037T3 (pl) |
FI (1) | FI3883936T3 (pl) |
HR (1) | HRP20231083T1 (pl) |
HU (1) | HUE062913T2 (pl) |
IL (1) | IL283333B2 (pl) |
LT (1) | LT3883936T (pl) |
MA (1) | MA55131B1 (pl) |
MX (1) | MX2021005714A (pl) |
PE (1) | PE20211870A1 (pl) |
PH (1) | PH12021551167A1 (pl) |
PL (1) | PL3883936T3 (pl) |
PT (1) | PT3883936T (pl) |
RS (1) | RS64579B1 (pl) |
SG (1) | SG11202104206SA (pl) |
SI (1) | SI3883936T1 (pl) |
TW (1) | TWI825227B (pl) |
UA (1) | UA128505C2 (pl) |
WO (1) | WO2020104494A1 (pl) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
WO2019105915A1 (en) | 2017-11-28 | 2019-06-06 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
DK3837263T3 (da) | 2018-08-13 | 2024-09-09 | Hoffmann La Roche | Nye heterocykliske forbindelser som monoacylglycerollipasehæmmere |
US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
KR20220062515A (ko) | 2019-09-12 | 2022-05-17 | 에프. 호프만-라 로슈 아게 | Magl 억제제로서 4,4a,5,7,8,8a-헥사피리도[4,3-b][1,4]옥사진-3-온 화합물 |
MX2023002224A (es) | 2020-09-03 | 2023-03-15 | Hoffmann La Roche | Compuestos heterociclicos. |
EP4215526A4 (en) * | 2020-09-18 | 2024-10-16 | Shanghai Pharmaceuticals Holding Co., Ltd. | HETEROCYCLIC CARBONYL COMPOUND AND ITS USE |
BR112023015210A2 (pt) | 2021-01-29 | 2023-11-07 | Cedilla Therapeutics Inc | Inibidores de cdk2 e métodos de uso dos mesmos |
CA3225439A1 (en) | 2021-06-26 | 2022-12-29 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
WO2023130050A1 (en) * | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain |
US20250084065A1 (en) | 2021-12-29 | 2025-03-13 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
US20250170100A1 (en) * | 2021-12-29 | 2025-05-29 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment of anxiety and related conditions |
US20250099448A1 (en) * | 2022-01-25 | 2025-03-27 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
WO2023247670A1 (en) * | 2022-06-24 | 2023-12-28 | F. Hoffmann-La Roche Ag | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
EP4568972A1 (en) | 2022-08-08 | 2025-06-18 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
KR20250044684A (ko) * | 2022-08-11 | 2025-04-01 | 레민드 엔.브이. | 신경퇴행성 질환 치료용 (아자)스피로헵탄 유도체 |
EP4590673A1 (en) * | 2022-09-20 | 2025-07-30 | F. Hoffmann-La Roche AG | Fluorescent probes for magl |
TW202428574A (zh) * | 2022-10-24 | 2024-07-16 | 瑞士商赫孚孟拉羅股份公司 | 新穎雜環化合物 |
WO2025068347A1 (en) | 2023-09-28 | 2025-04-03 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
KR101481872B1 (ko) | 2009-09-10 | 2015-01-12 | 에프. 호프만-라 로슈 아게 | Jak의 억제제 |
WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
US10106556B2 (en) * | 2015-03-30 | 2018-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
CN107849015B (zh) | 2015-05-21 | 2021-03-19 | 葛兰素知识产权发展有限公司 | 作为pad4抑制剂的苯并咪唑衍生物 |
CU20170166A7 (es) | 2015-07-31 | 2018-03-13 | Pfizer | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1, 1, 1-trifluoro-4-hidroxibutan-2-il carbamato como inhibidores de magl |
US10385057B2 (en) | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
JP2022548018A (ja) * | 2019-09-12 | 2022-11-16 | エフ.ホフマン-ラ ロシュ アーゲー | 放射性標識化合物 |
-
2019
- 2019-11-20 PE PE2021000714A patent/PE20211870A1/es unknown
- 2019-11-20 FI FIEP19809026.8T patent/FI3883936T3/fi active
- 2019-11-20 MX MX2021005714A patent/MX2021005714A/es unknown
- 2019-11-20 BR BR112021009348-6A patent/BR112021009348A2/pt unknown
- 2019-11-20 CA CA3119506A patent/CA3119506A1/en active Pending
- 2019-11-20 CN CN201980077284.5A patent/CN113166170A/zh active Pending
- 2019-11-20 SI SI201930619T patent/SI3883936T1/sl unknown
- 2019-11-20 MA MA55131A patent/MA55131B1/fr unknown
- 2019-11-20 KR KR1020217015287A patent/KR20210094540A/ko active Pending
- 2019-11-20 CR CR20210247A patent/CR20210247A/es unknown
- 2019-11-20 AU AU2019383500A patent/AU2019383500A1/en active Pending
- 2019-11-20 SG SG11202104206SA patent/SG11202104206SA/en unknown
- 2019-11-20 DK DK19809026.8T patent/DK3883936T3/da active
- 2019-11-20 PL PL19809026.8T patent/PL3883936T3/pl unknown
- 2019-11-20 PT PT198090268T patent/PT3883936T/pt unknown
- 2019-11-20 RS RS20230788A patent/RS64579B1/sr unknown
- 2019-11-20 ES ES19809026T patent/ES2955037T3/es active Active
- 2019-11-20 HU HUE19809026A patent/HUE062913T2/hu unknown
- 2019-11-20 LT LTEPPCT/EP2019/081870T patent/LT3883936T/lt unknown
- 2019-11-20 WO PCT/EP2019/081870 patent/WO2020104494A1/en active IP Right Grant
- 2019-11-20 IL IL283333A patent/IL283333B2/en unknown
- 2019-11-20 EP EP19809026.8A patent/EP3883936B1/en active Active
- 2019-11-20 HR HRP20231083TT patent/HRP20231083T1/hr unknown
- 2019-11-20 UA UAA202103201A patent/UA128505C2/uk unknown
- 2019-11-20 JP JP2021528972A patent/JP7444882B2/ja active Active
- 2019-11-21 TW TW108142267A patent/TWI825227B/zh active
- 2019-11-21 AR ARP190103417A patent/AR117139A1/es unknown
-
2021
- 2021-05-20 CL CL2021001330A patent/CL2021001330A1/es unknown
- 2021-05-20 US US17/325,934 patent/US20210387999A1/en active Pending
- 2021-05-21 PH PH12021551167A patent/PH12021551167A1/en unknown
- 2021-05-28 CO CONC2021/0007056A patent/CO2021007056A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283333A (en) | Heterocyclic compounds | |
HUE070093T2 (hu) | Heterociklusos vegyületek mint immunmodulátorok | |
PT4212529T (pt) | Compostos heterocíclicos como imunomoduladores | |
IL280821A (en) | Heterocycline compound | |
IL289595A (en) | Heterocyclic compounds | |
IL289617A (en) | Heterocyclic compounds | |
ZA202104402B (en) | Heterocyclic compound | |
IL288987A (en) | New heterocyclic compounds | |
GB201811169D0 (en) | New compounds | |
PT3643718T (pt) | Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1 | |
EP3660003C0 (en) | HETEROCYCLIC COMPOUND | |
SG11202009356RA (en) | Heterocyclic compound | |
GB201810668D0 (en) | New compounds | |
GB201810669D0 (en) | New compounds | |
GB201915191D0 (en) | Novel heterocyclic compounds | |
ZA201907792B (en) | Heterocyclic compound | |
GB201806488D0 (en) | Heterocyclic TADF compounds | |
IL277340A (en) | The orthocyclic compound | |
GB201808580D0 (en) | Heterocyclic compounds | |
ZA201907793B (en) | Heterocyclic compound | |
GB201817634D0 (en) | New compounds | |
GB201813681D0 (en) | New compounds | |
GB201805945D0 (en) | New compounds | |
GB201804745D0 (en) | New compounds | |
GB201802077D0 (en) | New compounds |